By mapping genomic profiles of driver gene mutations onto the structure of epidermal growth factor receptor (EGFR), four druggable mutations have been discovered that can be used to design personalized NSCLC treatments [36]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.